PubMed Health⌕ Search

Biomedical subjects

Frederick Kaskel

Publications and source records attributed to Frederick Kaskel.

8 recordsLinked to original sources
PubMed2006

The association of anemia and hypoalbuminemia with accelerated decline in GFR among adolescents with chronic kidney disease.

We sought to describe rates of kidney function decline and to identify modifiable risk factors for CKD progression in a multicenter prospective cohort study of adolescents with CKD aged 11 to 18 years seen semiannually for up to three years. Of the 23 subjects meeting inclusion criteria, the average estimated GFR was 51 +/- 27 ml/min/1.73 m(2) (0.85 +/- 0.45 ml/s/1.73 m(2)) at entry. The overall annualized decline in GFR was 5.6 ml/min/1.73 m(2) (0.093 ml/s/1.73 m(2)) per year (95% confidence interval [95% CI]: 1.9 to 9.3 [0.032 to 0.16]). The adjusted annualized decline in GFR was found to be accelerated in males, as well as among those over 15 years of age. The adjusted annualized decline in GFR was greater among those with either anemia (hematocrit below 36%), or hypoalbuminemia (albumin below 4 g/dl [40 g/L]). After adjustment, anemia was associated with an accelerated decline of 7.8 ml/min/1.73 m(2) (0.13 ml/s/1.73 m(2)) (95% CI: 3.3 to 12 [0.055 to 0.20]) and hypoalbuminemia was associated with an accelerated decline of 17 ml/min/1.73 m(2) (0.28 ml/s/1.73 m(2)) (95% CI: 11 to 22 [0.18 to 0.37]). Further study is needed to evaluate whether treatment of anemia or hypoalbuminemia, as outlined in current clinical care guidelines for CKD, may slow the progression of CKD in adolescents.

Adolescent↗
PubMed2005

Role of folate deficiency on erythropoietin resistance in pediatric and adolescent patients on chronic dialysis.

Unlike iron therapy, folate use is not a standard of care in hemodialysis (HD) patients. Despite iron repletion, poor response to erythropoietin (EPO) treatment is common. Theoretical evidence for folate deficiency (FD) includes chronic blood loss, inflammation, malnutrition, and nutrient loss during dialysis. Due to poor diagnostic standards, early studies failed to establish a role for FD in EPO resistance. Given that hematological response to therapeutic intervention is the gold standard for FD, its diagnosis was therefore based on composite scoring of RBC and/or folate indices. Fifteen subjects (8-20 years) on chronic HD were enrolled in this study. No folate supplement was given in the first six months. Thereafter, 5-mg folic acid was administered orally after HD sessions over a six-month period. Folate indices before and after treatment were compared using percentage differences and paired t-tests. After folate use, the mean Hb increased by 11.4%, while MCV and RDW were reduced. Similarly, 4 of the 15 subjects each had a > or = 20% rise in Hb and a > or = 5% reduction in MCV, while 46.7% had a > or = 2.5% reduction in RDW. Mean RBC folate increased by 24%, while FD scores reduced from 3.8+/-1.2 to 0.4+/-0.7, and the EPO requirement by 90%. In contrast to previous studies, 26.7% of study subjects met the criteria for FD. Furthermore, the substantial (post-folate) reduction in the EPO requirement validates the need for therapeutic intervention, and therefore the presence of functional FD in the population.

Adolescent↗
PubMed2004

Anemia and health-related quality of life in adolescents with chronic kidney disease.

BACKGROUND: A number of studies of adults with chronic kidney disease (CKD) have shown a negative impact of anemia on several aspects of health-related quality of life (HRQOL). Although similar links have been suggested in adolescent dialysis populations, the relationship between anemia and HRQOL in children not requiring dialysis therapy has yet to be studied extensively in a large sample. METHODS: We examined the association between anemia and HRQOL in baseline data collected on a prospective cohort of adolescents with CKD by using a generic HRQOL questionnaire completed by parents or caregivers (Child Health Questionnaire Parent Form [CHQ-PF50]). Our study population included guardians or caregivers of 105 adolescents (mean age, 14 +/- 2 years) with stages 1 to 5 CKD as defined by the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative, including subjects with chronic renal insufficiency, patients with functioning kidney transplants, and dialysis patients. RESULTS: Seventy of 105 patients were classified in the study as anemic according to a hematocrit value of 36% or less. Compared with the group with higher hematocrit values and independent of sex, race, and estimated glomerular filtration rate, anemic patients reported greater limitations in CHQ-PF50 domains relating to (1) physical functioning, (2) limitations in schoolwork or activities with friends as a result of physical health, and (3) parental impact in time and family activities. CONCLUSION: Anemia was associated with lower quality of life in adolescents across the spectrum of stages of CKD. Future studies should address the effect of interventions to improve anemia on HRQOL.

Adolescent↗
PubMed2004

Rationale for growth hormone therapy in children with chronic kidney disease.

Growth retardation is a common complication in children with chronic kidney disease. Treatable causes of growth retardation in these patients include renal osteodystrophy, metabolic acidosis, and inadequate nutritional intake. In addition, disturbances in the growth hormone-insulinlike growth factor I axis are a major cause of decreased growth. Administration of recombinant human growth hormone can overcome this problem, allowing catch-up growth and achievement of normal or improved adult height.

Adolescent↗
PubMed2002

Role of nitric oxide, endothelin-1, and inflammatory cytokines in blood pressure regulation in hemodialysis patients.

BACKGROUND: Altered regulation of blood pressure (BP) in hemodialysis patients is associated with increased morbidity and mortality. Regulation of BP is dependent in part on such vasoactive agents as nitric oxide (NO) and endothelin-1 (ET-1). Cytokine-mediated NO synthase activation during dialysis previously has been reported. The purpose of this study is to investigate the relationship between cytokine-mediated activation of the NO and ET-1 systems and BP regulation in hemodialysis patients. METHODS: Nine patients with chronic hypotension (predialysis systolic BP < 110 mm Hg, duration > 1 month), nine patients with hypertension (predialysis systolic BP > or = 180 mm Hg), and nine age- and sex-matched normotensive controls were enrolled. RESULTS: Predialysis NO end product levels in the hypotensive group were greater than in controls (17.63 +/- 5.9 versus 11.06 +/- 2.12 microm/mL; P = 0.01), whereas the hypertensive group showed lower levels (4.76 +/- 2.33 microm/mL; P < 0.01). The hypotensive group had low postdialysis levels (3.45 +/- 1.11 microm/mL; P = 0.01). Predialysis ET-1 levels in the hypotensive and hypertensive groups were greater in comparison to the normotensive group (7.54 +/- 4.52 and 8.95 +/- 3.52 versus 4.41 +/- 0.6 pg/mL; P < 0.01). Postdialysis endothelin levels increased in both the control and hypertensive groups (P < 0.01). Interleukin-1 and tumor necrosis factor-alpha levels increased postdialysis in all groups, but not significantly. CONCLUSION: High levels of NO end products in hypotensive patients and low levels in hypertensive patients suggest a critical influence of NO in BP control. In addition, elevated ET-1 levels in hypertensive patients may contribute to systemic vasoconstriction and may suggest vascular dysfunction in this patient population.

Adolescent↗